Interferons are currently undergoing clinical testing in patients with cancer and other diseases. A variety of routes of administration are being utilized, and there is particular interest in delivery of interferon to the central nervous system. A biphasic decline in plasma concentrations was observed in monkeys following an i.v. bolus, with initial half-times of 15 to 33 min and terminal half-times of 1.7 to 4.6 hours. Total body clearance ranged from 24 to 39 ml/sq. m/min and steady-state volume of distribution was similar to extracellular space. CSF exposure was 1% or less than that of plasma. Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%). Levels in the CSF were not detectable for the i.m. route. For intraventricular doses, CSF exposure was 3,000-fold greater than for i.v. doses, despite a 20-fold lower dose
Collins, J., Riccardi, R., Trown, P., Oneill, D., Poplack, D., PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF RECOMBINANT INTERFERON ALPHA-A IN MONKEYS - COMPARISON OF INTRAVENOUS, INTRAMUSCULAR, AND INTRAVENTRICULAR DELIVERY, <<CANCER DRUG DELIVERY>>, 1985; 2 (4): 247-253. [doi:10.1089/cdd.1985.2.247] [http://hdl.handle.net/10807/16896]
PLASMA AND CEREBROSPINAL-FLUID PHARMACOKINETICS OF RECOMBINANT INTERFERON ALPHA-A IN MONKEYS - COMPARISON OF INTRAVENOUS, INTRAMUSCULAR, AND INTRAVENTRICULAR DELIVERY
Riccardi, Riccardo;
1985
Abstract
Interferons are currently undergoing clinical testing in patients with cancer and other diseases. A variety of routes of administration are being utilized, and there is particular interest in delivery of interferon to the central nervous system. A biphasic decline in plasma concentrations was observed in monkeys following an i.v. bolus, with initial half-times of 15 to 33 min and terminal half-times of 1.7 to 4.6 hours. Total body clearance ranged from 24 to 39 ml/sq. m/min and steady-state volume of distribution was similar to extracellular space. CSF exposure was 1% or less than that of plasma. Intramuscular injections produced lower peak concentrations and more sustained levels, but there was substantial variation in bioavailability (range 19-103%). Levels in the CSF were not detectable for the i.m. route. For intraventricular doses, CSF exposure was 3,000-fold greater than for i.v. doses, despite a 20-fold lower dose
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
